Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLI1 | P08151 | 2/20 | 0.66 |
| ▸ | SCN4A | P35499 | 1/20 | 0.54 |
| ▸ | NOS2 | P35228 | 2/20 | 0.43 |
| ▸ | NOS3 | P29474 | 1/20 | 0.43 |
| ▸ | NOS1 | P29475 | 1/20 | 0.43 |
| ▸ | PRCP | P42785 | 1/20 | 0.41 |
| ▸ | DPP4 | P27487 | 5/20 | 0.41 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.40 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.40 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.39 |
| ▸ | FAP | Q12884 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL255493 | 1.00 | GLI1 (0.66) | GLI1SCN4ANOS2NOS3NOS1 | |
| SCHEMBL894617 | 1.00 | GLI1 (0.66) | GLI1SCN4ANOS2NOS3NOS1 | |
| Hydrochloric Acid SCHEMBL27654729 | 0.98 | GLI1 (0.63) | GLI1SCN4ANOS2NOS3NOS1 | |
| Hydrochloric Acid SCHEMBL490043 | 0.98 | GLI1 (0.63) | GLI1SCN4ANOS2NOS3NOS1 | |
| SCHEMBL28418653 | 0.98 | GLI1 (0.63) | GLI1SCN4ANOS2NOS3NOS1 | |
| Hydrochloric Acid SCHEMBL6387850 | 0.98 | GLI1 (0.63) | GLI1SCN4ANOS2NOS3NOS1 | |
| SCHEMBL16992331 | 0.94 | GLI1 (0.58) | GLI1SCN4ANOS2NOS3NOS1 | |
| SCHEMBL3832254 | 0.94 | GLI1 (0.58) | GLI1SCN4ANOS2NOS3NOS1 | |
| SCHEMBL2917600 | 0.94 | GLI1 (0.58) | GLI1SCN4ANOS2NOS3NOS1 | |
| Hydrochloric Acid SCHEMBL5430649 | 0.92 | GLI1 (0.56) | GLI1SCN4ANOS2NOS3NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105073746-A | Substituted imidazopyridines as HDM2 inhibitors | MERCK SHARP & DOHME | 2015-11-18 | — | — | CN | claimed |
| CN-104918940-A | Purine inhibitors of human phosphatidylinositol 3-kinase | MERCK SHARP & DOHME | 2015-09-16 | — | — | CN | claimed |
| CN-102625799-A | Heterocyclic compounds and their uses | AMGEN INC | 2012-08-01 | — | — | CN | claimed |
| US-20070197577-A1 | Inhibitors of anthrax lethal factor | CENGENT THERAPEUTICS (US) | 2007-08-23 | — | — | US | claimed |
| US-9567304-B2 | Quinazolinedione derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2017-02-14 | — | — | US | disclosed |
| US-9567304-B2 | Quinazolinedione derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2017-02-14 | — | — | US | disclosed |
| US-9567304-B2 | Quinazolinedione derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2017-02-14 | — | — | US | disclosed |
| EP-2842946-B1 | QUINAZOLINEDIONE DERIVATIVE | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2016-09-28 | — | — | EP | disclosed |
| EP-2842946-B1 | QUINAZOLINEDIONE DERIVATIVE | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2016-09-28 | — | — | EP | disclosed |
| EP-2438989-B1 | USE OF ASYMMETRIC HYDROGENATION CATALYST | TAKASAGO PERFUMERY CO LTD (JP) | 2016-04-13 | — | — | EP | disclosed |
| CN-105073746-A | Substituted imidazopyridines as HDM2 inhibitors | MERCK SHARP & DOHME | 2015-11-18 | — | — | CN | disclosed |
| CN-104918940-A | Purine inhibitors of human phosphatidylinositol 3-kinase | MERCK SHARP & DOHME | 2015-09-16 | — | — | CN | disclosed |
| US-20070161615-A1 | Chemical compounds | ASTRAZENECA AB (SE) | 2007-07-12 | — | — | US | disclosed |
| EP-1748999-A1 | IMIDAZOLO-5-YL-2-ANILINOPYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION | AstraZeneca AB (SE) | 2007-02-07 | — | — | EP | disclosed |
| CN-1886399-A | Quinazoline derivatives | ASTRAZENECA AB (SE) | 2006-12-27 | — | — | CN | disclosed |
| CN-1882576-A | Quinazoline derivatives | ASTRAZENECA AB (SE) | 2006-12-20 | — | — | CN | disclosed |
| US-20060025432-A1 | Pyrimidyl sulphone amide derivatives as chemokine receptor modulators | ASTRAZENECA AB (SE) | 2006-02-02 | — | — | US | disclosed |
| CN-1681795-A | Pyrimidyl sulfonamide derivatives as chemokine receptor modulators | ASTRAZENECA AB (SE) | 2005-10-12 | — | — | CN | disclosed |
| WO-2005075461-A1 | IMIDAZOLO-5-YL-2-ANILINOPYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION | ASTRAZENECA AB (SE) | 2005-08-18 | — | — | WO | disclosed |
| WO-2005027856-A2 | INHIBITORS OF ANTHRAX LETHAL FACTOR | CENGENT THERAPEUTICS (US) | 2005-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197577-A1 | Inhibitors of anthrax lethal factor | APAF1, ANTXR2, LITAF | GLI1 4094/4885SCN4A 3701/4885NOS2 2431/4885 |
| US-20070161615-A1 | Chemical compounds | MKI67, PCNA, CCNI | GLI1 3498/4885SCN4A 4050/4885NOS2 1181/4885 |
| US-20060025432-A1 | Pyrimidyl sulphone amide derivatives as chemokine receptor modulators | ACKR3, GPR17, CCL11 | GLI1 3697/4885SCN4A 2893/4885NOS2 3449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.